A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 5, 2013, Pages 1103-1110

  Raez, Luis E ^a   Santos, Edgardo S ^b   Webb, R Timothy ^c   Wade, James ^d   Brito, Roger A ^e   Karr, Melissa ^f   Kennah, Andra ^g   Childs, Barrett H ^g  

^a Memorial Health Care System   (United States)

^b BOCA RATON REGIONAL HOSPITAL   (United States)

^c Genesis Cancer Center   (United States)

^d Decatur Memorial Hospital   (United States)

^e Hematology and Medical Oncology   (United States)

^f UNIVERSITY OF MIAMI   (United States)

^g SANOFI   (France)

Author keywords

Bevacizumab; Docetaxel; Metastatic disease; Non small cell lung cancer; Oxaliplatin

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; METOCLOPRAMIDE; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; TAXOID;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; APPENDICITIS; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANDIDIASIS; CELLULITIS; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ESOPHAGOBRONCHIAL FISTULA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPONATREMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; INTESTINE PERFORATION; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SPINAL CORD COMPRESSION; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PATHOLOGY; SECONDARY; SURVIVAL;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84887153000     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2301-z     Document Type: Article

References (33)

1. Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024 (Pubitemid 46606280)
2. Georgoulias V, Ardavanis A, Agelidou A et al (2004) Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 22:2602-2609 (Pubitemid 41103747)
3. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103 (Pubitemid 30324363)
4. Dancey J, Shepherd FA, Gralla RJ et al (2004) Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 43:183-194 (Pubitemid 38114747)
5. Kouroussis C, Agelaki S, Mavroudis D et al (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23:785-791 (Pubitemid 36358489)
6. Raez LE, Santos ES, Lopes G et al (2006) Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer 53:347-353 (Pubitemid 44189568)
7. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
8. Manegold C, von Pawel J, Zatloukal P (2007) Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25((18 suppl)):LBA7514
9. Patel JD, Hensing TA, Rademaker A et al (2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27:3284-3289
10. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
11. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98 (Pubitemid 34438899)
12. Chow SC, Shao J, Wang H (eds) (2003) Sample size calculations in clinical research. CRC Press, New York, NY
13. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
14. Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29-41
15. Kalbfleisch JD, Prentice RL (2002) The statistical analysis of failure time data, 2nd edn. John Wiley & Sons, Inc., New York, NY
16. William WN Jr, Kies MS, Fossella FV et al (2010) Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 116:2401-2408
17. Reck M, von Pawel J, Zatloukal P et al (2010) for the BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol 21:1804-1809
18. Kubota K, Kawahara M, Ogawara M et al (2008) for the Japan Multi-National Trial Organisation. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 9:1135-1142
19. Dols MC, Chamorro EV, Díaz IA (2006) Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Clin Transl Oncol 8:742-749
20. Laack E, Dickgreber N, Müller T et al (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22:2348-2356 (Pubitemid 41115391)
21. Rixe O, Ortuzar W, Alvarez A et al (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865 (Pubitemid 26419675)
22. Schmidt W, Chaney SG (1993) Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805 (Pubitemid 23077865)
23. Rietbroek RC, van de Vaart PJM, Haveman J et al (1997) Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 123:6-12 (Pubitemid 26414189)
24. Mamenta EL, Poma EE, Kaufmann WK et al (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500-3505 (Pubitemid 24225973)
25. Chang MH, Kim KH, Jun HJ et al (2009) Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 64:917-924
26. Radhakrishnann A, Bitran JD, Milton DT et al (2009) Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial. J Chemother 21:439-444
27. Trédaniel J, Becht C, Bekradda M et al (2009) An open phase II trial of gemcitabine, oxaliplatin, and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients. Lung Cancer 63:259-263
28. Heist RS, Fidias P, Huberman M et al (2008) A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol 3:1153-1158
29. Lilenbaum R, Raez L, Tseng J et al (2008) Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 3:511-515 (Pubitemid 351630279)
30. Kakolyris S, Ziras N, Vamvakas L et al (2006) Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small-cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer 54:347-352 (Pubitemid 44634148)
31. Cappuzzo F, Novello S, De Marinis F et al (2005) Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 93:29-34 (Pubitemid 41076249)
32. Winegarden JD, Mauer AM, Otterson GA et al (2004) A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 15:915-920 (Pubitemid 39004347)
33. Monnet I, de Cremoux H, Soulié P et al (2002) Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 13:103-107 (Pubitemid 34436733)